Unicycive Therapeutics Inc (NASDAQ:UNCY) shares, rose in value on Thursday, April 16, with the stock price up by 0.38% to the previous day’s close as strong demand from buyers drove the stock to $0.60.
Actively observing the price movement in the last trading, the stock closed the session at $0.60, falling within a range of $0.5975 and $0.61. The value of beta (5-year monthly) was 2.147. Referring to stock’s 52-week performance, its high was $1.29, and the low was $0.20. On the whole, UNCY has fluctuated by -9.58% over the past month.
With the market capitalization of Unicycive Therapeutics Inc currently standing at about $71.86 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-30.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that UNCY’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Buy while long-term indicators on average have been pointing out that it is a 50% Buy.
The stock’s technical analysis shows that the price of UNCY currently trading nearly 4.26% and 4.31% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 54.21, while the 7-day volatility ratio is showing 8.22% which for the 30-day chart, stands at 11.07%. Furthermore, Unicycive Therapeutics Inc (UNCY)’s beta value is 2.05, and its average true range (ATR) is 0.06.
A comparison of Unicycive Therapeutics Inc (UNCY) with its peers suggests the former has fared considerably weaker in the market. UNCY showed an intraday change of 0.38% in last session, and over the past year, it shrunk by -46.40%%.
Data on historical trading for Unicycive Therapeutics Inc (NASDAQ:UNCY) indicates that the trading volumes over the past 10 days have averaged 0.96 and over the past 3 months, they’ve averaged 983.26K. According to company’s latest data on outstanding shares, there are 113.84 million shares outstanding.
Nearly 17.08% of Unicycive Therapeutics Inc’s shares belong to company insiders and institutional investors own 53.77% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.71 million shares as on 2025-03-31, resulting in a short ratio of 2.07. According to the data, the short interest in Unicycive Therapeutics Inc (UNCY) stood at 152.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 1.4 million. The stock has fallen by -24.41% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the UNCY stock heading into the next quarter.
